Skip to main content
. 2012 Oct 31;32(44):15476–15488. doi: 10.1523/JNEUROSCI.2429-12.2012

Figure 6.

Figure 6.

Involvement of OXTR/PLC and EGFR transactivation in OXT-induced increases in PKMξ synthesis. A, B, Representative immunoblot and summary histogram showing pretreatment of the synaptoneurosomes with OXTR antagonist L-371257 (3 μm) or PLC blocker U73122 (10 μm) blocked OXT (1 μm)-induced increases in PKMξ synthesis. C, Representative immunoblot and summary histogram showing OXT (1 μm)-induced increases in PKMξ expression in the synaptoneurosomes was blocked by pretreatment with EGFR inhibitor AG1478 (1 μm), PI3K inhibitor LY294002 (20 μm), or MAPK kinase inhibitor U0126 (10 μm). D, Summary of experiments showing pretreatment of hippocampal slices with AG1478 (1 μm) blocked OXT (1 μm)-induced enhancement of LTP. Representative traces of fEPSPs were taken at the time indicated by number. Dash lines show level of baseline. E, Representative immunoblot and summary histogram showing OXT (1 μm)-induced increases in PKMξ expression were not affected by pretreatment of the synaptoneurosomes with Trk family of receptor tyrosine kinase inhibitor K252a (0.2 μm). The total number of experiments is indicated by n in parenthesis. Data are represented as mean ± SEM. *p < 0.05 compared with vehicle-treated group.